Sunday, September 19, 2021
wellness India Expo
Home Tags ILUMYA

Tag: ILUMYA

Sun Pharma announces 5-year sustained efficacy & safety results for its...

ILUMYA is the first IL-23 inhibitor to complete five years of study based on a pooled analysis of two Phase 3 efficacy and safety extension trials in moderate-to-severe plaque psoriasis.......................

Sun Pharma’s plaque psoriasis drug ILUMYA gets approval in Japan

The drug offers a new treatment option with only one injection every 12 weeks for Japanese patients who struggle everyday with the chronic nature of plaque psoriasis..........................

Sun Pharma inks deals with Hikma Pharma over distribution of psoriasis...

Sun Pharma and Hikma have entered into an exclusive licensing agreement for ILUMYA for the Middle East and North Africa regions...................